S-layer protein 2 of vaginal Lactobacillus crispatus 2029 enhances growth, differentiation, VEGF production and barrier functions in intestinal epithelial cell line Caco-2.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
31 Oct 2021
Historique:
received: 02 07 2021
revised: 11 08 2021
accepted: 18 08 2021
pubmed: 27 8 2021
medline: 29 12 2021
entrez: 26 8 2021
Statut: ppublish

Résumé

We have previously demonstrated the ability of the human vaginal strain Lactobacillus crispatus 2029 (LC2029) for strong adhesion to cervicovaginal epithelial cells, expression of the surface layer protein 2 (Slp2), and antagonistic activity against urogenital pathogens. Slp2 forms regular two-dimensional structure around the LC2029 cells,which is secreted into the medium and inhibits intestinal pathogen-induced activation of caspase-9 and caspase-3 in the human intestinal Caco-2 cells. Here, we elucidated the effects of soluble Slp2 on adhesion of proteobacteria pathogens inducing necrotizing enterocolitis (NEC), such as Escherichia coli ATCC E 2348/69, E. coli ATCC 31705, Salmonella Enteritidis ATCC 13076, Campylobacter jejuni ATCC 29428, and Pseudomonas aeruginosa ATCC 27853 to Caco-2 cells, as well as on growth promotion, differentiation, vascular endothelial growth factor (VEGF) production, and intestinal barrier function of Caco-2 cell monolayers. Slp2 acts as anti-adhesion agent for NEC-inducing proteobacteria, promotes growth of immature Caco-2 cells and their differentiation, and enhances expression and functional activity of sucrase, lactase, and alkaline phosphatase. Slp2 stimulates VEGF production, decreases paracellular permeability, and increases transepithelial electrical resistance, strengthening barrier function of Caco-2 cell monolayers. These data support the important role of Slp2 in the early postnatal development of the human small intestine enterocytes.

Identifiants

pubmed: 34437917
pii: S0141-8130(21)01815-8
doi: 10.1016/j.ijbiomac.2021.08.150
pii:
doi:

Substances chimiques

Membrane Glycoproteins 0
RNA, Messenger 0
S-layer proteins 0
Vascular Endothelial Growth Factor A 0
Alkaline Phosphatase EC 3.1.3.1
Lactase EC 3.2.1.108
Sucrase EC 3.2.1.48

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

410-419

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Vyacheslav M Abramov (VM)

Institute of Immunological Engineering, Lyubuchany 142380, Moscow Region, Russia; Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health, Moscow 117997, Russia.

Igor V Kosarev (IV)

Institute of Immunological Engineering, Lyubuchany 142380, Moscow Region, Russia; Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health, Moscow 117997, Russia.

Tatiana V Priputnevich (TV)

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health, Moscow 117997, Russia.

Andrey V Machulin (AV)

Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Science", Pushchino 142290, Moscow Region, Russia.

Tatiana N Abashina (TN)

Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Science", Pushchino 142290, Moscow Region, Russia.

Irina O Chikileva (IO)

Institute of Immunological Engineering, Lyubuchany 142380, Moscow Region, Russia; Laboratory of Cell Immunity, Blokhin National Research, Center of Oncology Ministry of Health RF, Moscow 115478, Russia.

Almira D Donetskova (AD)

NRC Institute of immunology FMBA of Russia, Moscow 115522, Russia.

Kazuhide Takada (K)

Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.

Vyacheslav G Melnikov (VG)

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare, Moscow 152212, Russia.

Raisa N Vasilenko (RN)

Institute of Immunological Engineering, Lyubuchany 142380, Moscow Region, Russia.

Valentin S Khlebnikov (VS)

Institute of Immunological Engineering, Lyubuchany 142380, Moscow Region, Russia.

Vladimir A Samoilenko (VA)

Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Science", Pushchino 142290, Moscow Region, Russia.

Ilya N Nikonov (IN)

Federal State Education Institution of Higher Professional Education Moscow State Academy of Veterinary Medicine and Biotechnology named after K.I. Skryabin, Moscow 109472, Russia.

Gennady T Sukhikh (GT)

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health, Moscow 117997, Russia.

Vladimir N Uversky (VN)

Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA. Electronic address: vuversky@usf.edu.

Andrey V Karlyshev (AV)

Department of Science, Engineering and Computing, Kingston University London, Kingston upon Thames KT1 2EE, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH